Monday, 3 July 2006
Drug companies and treatments for Macular Degeneration
Posted on 06:14 by Unknown
The biotech company, Genentech, has just won approval for Lucentis, a drug designed to treat patients with macular degeneration. This is fantastic news, of course, for patients with this condition. Doses of lucentis run are nearly $2000, though. Interestingly enough, Genentech has an anti-cancer drug, Avastin, which has been used off-label to treat about 10,000 MD patients. Avastin doses are only
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment